Jaena Han, Valentine Andreu, Cory Langreck, Elizabeth A Pekarskaya, Steven G Grinnell, Florence Allain, Valerie Magalong, John Pintar, Brigitte L Kieffer, Alexander Z Harris, Jonathan A Javitch, René Hen, Katherine M Nautiyal
Tianeptine is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). The recent discovery that tianeptine is a mu opioid receptor (MOR) agonist has provided a potential avenue for expanding our understanding of antidepressant treatment beyond the monoamine hypothesis. Thus, our studies aim to understand the neural circuits underlying tianeptine's antidepressant effects. We show that tianeptine induces rapid antidepressant-like effects in mice after as little as one week of treatment...
June 2022: Neuropsychopharmacology